Citi analyst Yigal Nochomovitz believes the setup for the next acquisition cycle in the biotech space is here, but that biotech management's desire to do deals is the missing catalyst. He thinks another one-to-three quarters is needed before "reset valuations are better absorbed as the new reality." Large cap pharma and biotech companies are cash rich and have signaled repeatedly over last year that they are looking for new assets, Nochomovitz tells investors in a research note. He sees a "greater probability" of a takeover over the next 12-18 months for Ardelyx (ARDX), Medivation (MDVN), Ophthotech (OPHT), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Ultragenyx (RARE), Relypsa (RLYP) and Versartis (VSAR). He sees a "moderate probability" of a takeover for Anthera (ANTH), Loxo Oncology (LOXO), MacroGenics (MGNX) and Mirati Therapeutics (MRTX). Nochomovitz also sees a "lower probability" of a buyout for Atara Biotherapeutics (ATRA), Chimerix (CMRX), Keryx (KERX) and Mirna Therapeutics (MIRN).